Mechanisms of Interaction Between Interferon Gamma and Antineoplastic Agents on Growth and Differentiation of Leukemic Cells: A Review

References

• Gresser I. How does interferon inhibit tumor growth. Interferon 6, I. Gresser. Academic Press, New York 1985; 1–12
   Google Scholar
• Brunda M. J., Wright R. B. Differential antiproliferative effects of recombinant interferon α and γ on two murine cell lines. Int. J. Cancer 1986; 37: 287–291
   PubMed Web of Science ®Google Scholar
• Denz H., Lechleitner M., Marth C., Daxenbichler G., Gastl G., Braunsteiner H. Effect of human recombinant α2 and γ interferon on the growth of human cell lines from solid tumor and hematologic malignancies. J. Interferon Res. 1985; 5: 147–157
   PubMedGoogle Scholar
• Ball E. D., Guyre P. M., Shen L., Glynn J. M., Maliszewski C. R., Baker P. E., Fanger M. W. Gamma interferon induces monocytoid differentiation in the HL-60 cell line. J. Clin. Invest. 1984; 73: 1072–1077
   PubMed Web of Science ®Google Scholar
• Takei M., Takeda K., Konno K. The role of interferon y in induction of differentiation of human myeloid leukemia cell lines, ML-1 and HL-60. Biochem. Biophys. Res. Comm. 1984; 124: 100–105
   PubMed Web of Science ®Google Scholar
• Pfeffernkorn L. C., Guyre P. M., Fanger M. W. Functional comparison of the inductions of NADPH oxidase activity and Fe gamma RI in IFN gamma-treated U937 cells. Mol. Immunol. 1990; 27: 263–272
   PubMed Web of Science ®Google Scholar
• Fisher P. B., Grant S. Effects of interferon on differentiation of normal tumor cells. Pharmacol. Ther. 1985; 11: 143–166
   Web of Science ®Google Scholar
• Sariban E., Mitchell T., Griffin J., Kufe D. W. Effects of interferon-y on proto-oncogene expression during induction. J. Immunol. 1987; 138: 1954–1958
   PubMed Web of Science ®Google Scholar
• Iwanami M., Takeda K., Konno K. Enhancement of interferon-γ induced differentiation of human monoblastic leukemia U937 cells by cAMP-inducing agents. J. Interferon Res. 1990; 10: 477–485
   PubMedGoogle Scholar
• Craig R. W., Buchan H. L. Differentiation-inducing and cytotoxic effects of tumor necrosis factor and interferon-gammain myeloblasts ML-1 cells. J. Cell. Physiol. 1989; 141: 46–52
   PubMed Web of Science ®Google Scholar
• Faltynek C. R., Finch L. R., Miller P., Overton W. R. Treatment with recombinant I FN-y decreases cell surface CDH levels on peripheral blood monocytes and on myelomonocytic cell lines. J. Immunol. 1989; 142: 500–508
   PubMed Web of Science ®Google Scholar
• Delforge A., Vandenplas B., Lagneaux L., Loos M., Bron D., Debusscher L., Strykmans P. Influence of recombinant alpha and gamma interferons on the in vitro proliferation of myeloid leukemic progenitors. Eur. J. Haematol. 1990; 44: 307–311
   PubMed Web of Science ®Google Scholar
• Cassatella M. A., Hartman L., Perussia B., Trinchieri G. Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy chain gene expression and nicotinamideadenine dinucleotide phosphate hydrogenase oxidase in human leukemia myeloid cells. J. Clin. Invest. 1989; 83: 1570–1579
   PubMed Web of Science ®Google Scholar
• McGlave P., Mamus S., Vilen B., Dewald G. Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp. Hematol 1987; 15: 331–335
   PubMed Web of Science ®Google Scholar
• Geissler K., Tricot G., Leemhuis T., Walker E., Broxmeyer H. E. Differentiation-inducing effect of recombinant human tumor necrosis factor α and γ-interferon in vitro on blast cells from patients with acute myeloid leukemia and myeloid blast crisis of chronic myeloid leukemia. Cancer Res. 1989; 49: 3057–3062
   PubMed Web of Science ®Google Scholar
• Tanabe Y., Dan K., Kuriya S., Nomura T. Effects of recombinant human alpha-2b and gamma interferons on bone marrow megakaryocyte progenitors (CFU-Meg) from patients with chronic myelocytic leukemia. Rinsho Ketsveki 1989; 30: 1800–1805
   PubMedGoogle Scholar
• Novick D., Orchansky P., Revel M., Rubinstein M. The human interferon-y receptor: Purification, characterization and preparation of antibodies. J. Biol. Chem. 1987; 262: 8483–8487
   PubMed Web of Science ®Google Scholar
• Auget M. The interferon-gamma receptor: a comparison with other cytokine receptors. J. Interferon Res. 1990; 10: 551–558
   PubMedGoogle Scholar
• Watson R. B., Galvani D. W., Nash J. R., Cawley J. C. Gamma interferon receptor expression in haemic malignancies. Leuk. Res. 1990; 14: 657–660
   PubMed Web of Science ®Google Scholar
• Bartsch H. H., Pfizenmaier K., Hanusch A., Scheurich P., Ucer U., Nagel G. A. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavourable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant interferon alpha correlates with the degree of receptor down regulation. Int. J. Cancer 1989; 43: 235–240
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Cazzola M., Ganser A., Bergamachi G., Pedrazzoli P., Hoelzer D., Ascari E. Synergistic antiproliferative effect of recombinant interferon-γ with recombinant interferon-α on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). Blood 1988; 73: 1293–1299
   Google Scholar
• Ishii Y., Tsukagoshi S. The synergistic effect of human recombinant interferon alpha 2a in combination with interferon gamma and the induction of interferon alpha 2a receptor by interferon gamma. J. Pharmacobiodyn 1989; 12: 299–304
   PubMedGoogle Scholar
• Levy D. E., Lew D. J., Decker T., Kessler D. S., Darnell J. E. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF 3. EMBO J. 1990; 9: 1105–1111
   PubMed Web of Science ®Google Scholar
• Schiller J. H., Horisberer M. A., Bittner G., Carbin J. M., Storer B., Byrne G. I., Willson J. K., Borden E. C. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle. J. Biol. Response Mod. 1990; 9: 368–377
   PubMedGoogle Scholar
• Talpaz M., Kantarijan H. M., Kurzrock R., Gutterman J. U. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Seminars in Hematol. 1988; 25: 62–73
   PubMed Web of Science ®Google Scholar
• Kloke O., Becher R., Niederle N. Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukemia. Blut 1987; 55: 453–458
   PubMedGoogle Scholar
• Trinchieri G., Kobayashi M., Rosen M., Loudon R., Perussia B., Murphy M. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J. Exp. Med. 1986; 164: 1206–1225
   PubMed Web of Science ®Google Scholar
• Murphy M., Perussia B., Trinchieri G. Effects of recombinant tumor necrosis factor, lymphotoxin and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp. Hematol 1988; 16: 131–138
   PubMed Web of Science ®Google Scholar
• Nakaya K., Chou Deguchi S. Y., Nakumura Y. Induction of differentiation of human leukemia cells by various combinations of cytokines and low molecular weight inducers. Chem. Pharmac. Bull. Tokyo 1990; 38: 966–970
   PubMed Web of Science ®Google Scholar
• Lydig J., Li W. J., Lopez A. R., Garovoy M., Arlinghaus R., Deiseroth A. The TNF alpha and gamma interferon combination act synergistically to increase class I HLA antigen expression in blast crisis CML patients. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1989; 8: A715
   Google Scholar
• Wietzerbin J., Gaudelet C., Catinot L., Chebath J., Falcoff R. Synergistic effect of interferon -gamma and tumor necrosis factor -alpha on antiviral activity and (2′-5′)oligo A synthetase induction in myelomonocytic cell line. J. Leuc. Biol. 1990; 48: 149–155
   PubMed Web of Science ®Google Scholar
• Salzberg S., Hacohen D., David S., Dovrat S., Ahwan S., Gamliel H., Birnbaum M. Involvement of interferon-system in the regulation of cell growth and differentiation. Scanning Microsc. 1990; 4: 479–489
   PubMedGoogle Scholar
• Revel M., Chebath J. Interferon-activated genes. Trends in Biochem. Sci. 1986; 11: 166–170
   Web of Science ®Google Scholar
• Werner-Felmayer G., Werner E. R., Fuchs D., Hansen A., Reibnegger G., Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res. 1990; 50: 2863–2867
   PubMed Web of Science ®Google Scholar
• Kim M-Y., Linardic C., Obeid L., Hannon Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor a and γ-interferon. J. Biol. Chem. 1991; 266: 484–489
   PubMed Web of Science ®Google Scholar
• Michishita M., Yoshida Y., Uchino H., Nagata K. Induction of tumor necrosis factor-alpha and its receptor during differentiation in myeloid leukemic cells along the monocytic pathway. A possible regulatory mechanism for TNF-alpha production. J. Biol. Chem. 1990; 265: 8751–8759
   PubMed Web of Science ®Google Scholar
• Raitano A. B., Senderi P, Korc M. Upregulation of interferon-y binding by tumor necrosis factor and lymphotoxin: Disparate potencies of the cytokines and modulation of their effects by phorbol ester. J. Interferon Res. 1991; 11: 61–67
   PubMedGoogle Scholar
• Irvine A. E., Berney J. J., Francis G. E. Dissociation of the proliferation and differentiation stimuli of granulocyte colony stimulating factor (G-CSF). Leukemia 1990; 4: 203–209
   PubMed Web of Science ®Google Scholar
• Pawelec G., Schneider E., Ehninger G., Rehbeim A., Schmidt H. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukemia after in vivo treatment with interferon alpha. Cancer Immunol. Immunother. 1989; 29: 63–66
   PubMed Web of Science ®Google Scholar
• Hivroz C., Valle A., Brouer J. C., Banchereau J., Grillot Courvalin C. Regulation by interleukin 2 of CD23 expression of leukemic and normal B cells: comparison with interleukin 4. Eur. J. Immunol. 1989; 19: 1025–1030
   PubMed Web of Science ®Google Scholar
• Barber K. E., Crosier P. S., Purdie K. J., Buchanan J. M., Cattermole J. A., Watson J. D., Gillis S. Human interleukin 3: effects on normal and leukemic cells. Growth Factors 1989; 1: 101–114
   PubMedGoogle Scholar
• Yoshifumi K., Yoichi T., Atsushi H., Takanori A., et al. Synergistic effect of recombinant interferon-γ and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood 1991; 77: 2118–2121
   PubMed Web of Science ®Google Scholar
• Kamijo R., Takeda K., Nagumo M., Konno K. Effect of combinations of transforming growth factor-beta 1 and tumor necrosis factor on induction of differentiation of human myelogenous leukemia cell lines. J. Immunol. 1990; 144: 1311–1316
   PubMed Web of Science ®Google Scholar
• De-Benedetti F., Falk L. A., Ellingsworth L. R., Ruscetti F. W., Faltynek C. R. Synergy between transforming growth factor-beta and tumor necrosis factor-alpha in the induction of monocytic differentiation of human leukemic cell lines. Blood 1990; 75: 626–632
   PubMed Web of Science ®Google Scholar
• Cochran F. R., Finch-Arietta M. B. Regulation of interleukin-beta and tumor necrosis factor secretion by the human monocytic leukemia cell line THP-1. Agents Actions 1989; 27: 271–273
   PubMedGoogle Scholar
• Gaffney E. V., Stonner C. R., Lingenfelter S. E., Wagner L. A. Demonstration of IL-1 alpha and IL-1 beta secretion by the monocytic leukemia cell line THP-1. J. Immunol. Methods 1989; 122: 211–218
   PubMed Web of Science ®Google Scholar
• Takahashi S., Yamashita T., Eto Y., Shibani H., Miyamoto K., Ogata E. Inducible gene expression of activin A/erythroid differentiation factor in HL60 cells. Biochem. Biophys. Res. Commun. 1990; 167: 654–658
   PubMed Web of Science ®Google Scholar
• Ayroldi E., Blasi E., Varesio L., Wiltrout R. H. Synergistic antiproliferative effects on I FN gamma, ILI and TNF alpha for a retrovirus immortalized mouse myelomonocytic tumor. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1989; 30: A1617
   Google Scholar
• Lin J., Sartorelli A. C. Stimulation by interferon of the differentiation of human promyelocytic leukemia (HL-60) cells produced by retinoic acid and actinomycin D. J. Interferon Res. 1987; 7: 379–387
   PubMedGoogle Scholar
• Hemmi H., Breitman T. R. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987; 69: 501–507
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Rosen M., Perussia B. Retinoic acid cooperates with tumor necrosis factor and immune interferon in inducing differentiation and growth inhibition of the human promyelocytic leukemia cell line HL-60. Blood 1987; 69: 1218–1224
   PubMed Web of Science ®Google Scholar
• Gallagher R. E., Lurie K. Y., Leavitt R. D., Wiernik P. H. Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-αA interferon. Leukemia Res. 1987; 11: 609–619
   PubMed Web of Science ®Google Scholar
• Kohlepp E. A., Condon M E., Hamburger A. W. Recombinant human interferon α enhancement of retinoic-acid-induced differentiation of HL-60 cells. Exp. Hematol 1987; 15: 414–418
   PubMed Web of Science ®Google Scholar
• Grant S., Bhalla K., Weinstein B., Pestka S., Mileno N., Fisher P. B. Recombinant human interferon sensitizes resistant myeloid leukemic cells to induction of terminal differentiation. Biochem. Biophys. Res. Comm. 1985; 130: 379–388
   PubMed Web of Science ®Google Scholar
• Langer J. A., Pestka S. Changes in binding of alpha interferon IFN-aA to HL-60 cells during myeloid differentiation. J. Interferon Res. 1985; 5: 637–649
   PubMedGoogle Scholar
• Capeillere-Blandin C., Chauvet G., Tresset F., Descamps-Latscha B. Development of cytochrome b558 and oxidative metabolism in human granulocytes, monocytes and during differentiation of HL-60 and U937 cells. Biol. Cell 1990; 69: 73–82
   PubMed Web of Science ®Google Scholar
• Ho C. K., Wang C. Y., Ou B. R., Shiao M. S., Chen N. Y., Kuwata T. Enhancement of interferon induced 2-5 oligo adenylate synthetase activity by retinoic acid in human histiocytic U937 cells and WISH cells. Differentiation 1989; 40: 70–75
   PubMed Web of Science ®Google Scholar
• Hemmi H., Nakamura T., Goto Y., Sugamura K. Pertusis toxin inhibits differentiation induced by retinoic acid in a human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun. 1989; 163: 797–802
   PubMed Web of Science ®Google Scholar
• Kafka M., Nathan I., Dvilansky A. New combination of 5-fluorouracil and interferon γ effective against human myeloid leukemia in vitro. Anticancer Res. 1989; 9: 1037–1040
   PubMed Web of Science ®Google Scholar
• Harrison S. D., Stevens J. J., Wand W. R., Dykes D. J., Schmid S. M., Griswold D. P. Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo. J. Biol. Response Mod. 1990; 9: 395–400
   PubMedGoogle Scholar
• Namba M., Yamamoto S., Tanaka H., Kamamori T., Nobuhara M., Kimoto T. In vitro, in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt gamma ray by interferon on human neoplastic cells. Cancer 1987; 54: 2262–2267
   Web of Science ®Google Scholar
• Roberts P., Jones M., Gale R., Thomas S., Tidman N., Linch D. The c-myc oncogene is regulated independently of differentiation in myeloid cell lines. Leukemia Res. 1989; 13: 651–659
   PubMed Web of Science ®Google Scholar
• Chiba P., Tihan T., Eher R., Koller U., Wallner C., Gobi R., Linkesch W. Effect of cell growth and differentiation on 1-β-D-arabinofuranosylcytosine metabolism in myeloid cells. Brit. J. Haemal. 1989; 71: 451–455
   PubMed Web of Science ®Google Scholar
• Elias L., Crissman H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 1988; 48: 4868–4873
   PubMed Web of Science ®Google Scholar
• Kafka M., Dvilansky A., Nathan I. Mechanism of interaction between interferon γ and antineoplastic agents on the differentiation of HL60 promyelocytic cells. Exp. Hematoi 1990; 18: 153–158
   PubMed Web of Science ®Google Scholar
• Danenberg P. V., Lockshin A. Thymidilate synthetase-substrate complex formation. Mol. Cell. Biochem. 1982; 43: 49–57
   PubMed Web of Science ®Google Scholar
• Chu E., Zinn S., Boarman D., Allegra C. J. Interaction of γ-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990; 50: 5834–5840
   PubMed Web of Science ®Google Scholar
• Elias L., Sandoval J. M. Interferon effects upon fluorouracil metabolism by HL60 cells. Biochem. Biophys. Res. Comm. 1989; 163: 867–874
   PubMed Web of Science ®Google Scholar
• Pinedo H. M., Peters G. F. J. Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 1988; 6: 1653–1664
   PubMed Web of Science ®Google Scholar
• Elias L., Wood A., Crissman H. A., Rattlif R. Effects on condition medium upon proliferation, deoxynucleotide metabolism and antimetabolite sensitivity of promyelocytic leukemia in vitro. Cancer Res. 1985; 45: 6301–6307
   PubMed Web of Science ®Google Scholar
• Stolfi R. L., Martin D. S. Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon. J. Biol. Res. Med 1985; 4: 634–639
   PubMedGoogle Scholar
• Ligo M., Chapekar M. S., Glazer R. I. Synergistic antitumor effect of fluoropyrimidines and polyinosinicpolycytidylic acid against L1210 leukemia. Cancer Res. 1985; 45: 4039–4042
   PubMed Web of Science ®Google Scholar
• Morikawa K., Fan D., Denkins Y. M., Levin B., Gutterman J. U., Walker S. M., Fidler I. J. Mechanisms of combined effects of γ-interferon and 5-fluorouracil on human colon cancer implanted into nude mice. Cancer Res. 1989; 49: 799–805
   PubMed Web of Science ®Google Scholar
• Yoneda K., Yamamoto T., Osaki T. Enhanced cytotoxicity of antineoplastics by interferon. Nippon Gan Chiryo Gakkui Shi 1990; 25: 77–84
   PubMedGoogle Scholar
• Singh G., Renton K. W., Stebbing N. Homogenous interferon from E. coli depresses hepatic cytochrome P-450 drug biotransformation. Biochem. Biophys. Res. Commun. 1982; 106: 1256–1261
   PubMed Web of Science ®Google Scholar
• Balkwill F. R., Mowshowitz S., Seilman S. S., Moodie Griffin E. M., Fantes D. B.K. H., Wolf C. R. Positive interactions between interferon and chemotherapy due to direct tumor action rather than effect on host drug-metabolizing enzymes. Cancer Res. 1984; 44: 5249–5255
   PubMed Web of Science ®Google Scholar
• Moochhala S. M., Renton K. W. Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus a interferon (IFN-αCON1) in the hamster. Biochem. Pharmacol. 1987; 38: 439–447
   Web of Science ®Google Scholar
• Nichols K. E., Chitneni S. R., Moore J. O., Weinberg J. B. Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL60 cells induced by the glutamine antagonist acivicin. Blood 1989; 74(5)1728–1737
   PubMed Web of Science ®Google Scholar
• Visani G., Lemoli R. M., Tosi P., Verlicchi F., Gamber B., Cenacchi A. R., Columbini R., Fogli M., Russo D., Zuffa E. Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma. Blut 1990; 60: 287–290
   PubMedGoogle Scholar